Abstract
Breast cancer remains a leading cause of death despite early screening and advances in medicine. Bone marrow metastasis often complicates the clinical picture by requiring more aggressive treatment and worsening long-term prognoses. Recent therapeutic targeting of hormonal receptors such as human epidermal growth factor receptor 2 and estrogen receptor has shown limited success in treating localized disease for those patients whose cancer cells are responsive. Although traditional approaches such as chemotherapy have demonstrated many successes, these agents fail to target quiescent cancer stem cells, which might have entered the bone marrow where they might be responsible for the quiescence population. Following years of clinical remission, these dormant cells could lead to secondary cancer resurgence. To date, little progress has been made in the development of targeted treatments for receptor negative and metastatic disease. In this review, we discuss the role of G-protein coupled receptors, including neurokinin-1, neurokinin-2 and chemokine receptor 4, as novel targets in the treatment of breast cancer.
Keywords: CXCR-4, tachykinins, metastasis, chemokines, cancer, hematopoiesis
Mini-Reviews in Medicinal Chemistry
Title: G-Coupled Protein Receptors and Breast Cancer Progression: Potential Drug Targets
Volume: 7 Issue: 3
Author(s): Marcelo Taborga, Kelly E. Corcoran, Neil Fernandes, Shakti H. Ramkissoon and Pranela Rameshwar
Affiliation:
Keywords: CXCR-4, tachykinins, metastasis, chemokines, cancer, hematopoiesis
Abstract: Breast cancer remains a leading cause of death despite early screening and advances in medicine. Bone marrow metastasis often complicates the clinical picture by requiring more aggressive treatment and worsening long-term prognoses. Recent therapeutic targeting of hormonal receptors such as human epidermal growth factor receptor 2 and estrogen receptor has shown limited success in treating localized disease for those patients whose cancer cells are responsive. Although traditional approaches such as chemotherapy have demonstrated many successes, these agents fail to target quiescent cancer stem cells, which might have entered the bone marrow where they might be responsible for the quiescence population. Following years of clinical remission, these dormant cells could lead to secondary cancer resurgence. To date, little progress has been made in the development of targeted treatments for receptor negative and metastatic disease. In this review, we discuss the role of G-protein coupled receptors, including neurokinin-1, neurokinin-2 and chemokine receptor 4, as novel targets in the treatment of breast cancer.
Export Options
About this article
Cite this article as:
Taborga Marcelo, Corcoran E. Kelly, Fernandes Neil, Ramkissoon H. Shakti and Rameshwar Pranela, G-Coupled Protein Receptors and Breast Cancer Progression: Potential Drug Targets, Mini-Reviews in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/138955707780059826
DOI https://dx.doi.org/10.2174/138955707780059826 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued) MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised
Current Pharmaceutical Design Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Design, Synthesis and Anticancer Activity Against the MCF-7 Cell Line of Benzo-Fused 1,4-Dihetero Seven- and Six-Membered Tethered Pyrimidines and Purines
Current Medicinal Chemistry Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors
Current Pharmaceutical Design Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Atrial Fibrillation Recurrence: The Roles of Hypertension, Duration of Atrial Fibrillation Disease, and Prolonged Signal-Averaged P Wave Duration
Current Cardiology Reviews Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry